{"id":31214,"date":"2025-08-29T19:57:59","date_gmt":"2025-08-29T19:57:59","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/jacobio-pharma-announces-2025-interim-results\/"},"modified":"2025-08-29T19:57:59","modified_gmt":"2025-08-29T19:57:59","slug":"jacobio-pharma-announces-2025-interim-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31214","title":{"rendered":"Jacobio Pharma Announces 2025 Interim Results"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span> and <span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 30, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Jacobio Pharma (1167.HK) today announced its interim results for the six months ended <span class=\"xn-chron\">June 30, 2025<\/span>.<\/p>\n<p>During the reporting period, the Company achieved revenue of <span class=\"xn-money\">RMB45.7 million<\/span>, representing a 100% increase compared with the same period in 2024. Research and development (R&amp;D) expenses amounted to \u00a0RMB93.2 million. The net loss for the first half of 2025 was <span class=\"xn-money\">RMB59.0 million<\/span>, \u00a0narrowing by 65.1% compared with the same period in 2024. As of <span class=\"xn-chron\">June 30, 2025<\/span>, Jacobio maintained cash and bank balances, and investments in capital protected structure deposits, totaling <span class=\"xn-money\">RMB1,07billion<\/span>, along with <span class=\"xn-money\">RMB270 million<\/span> bank credit available which provides sufficient and stable liquidity to support our R&amp;D activities.<\/p>\n<p>Dr. Yinxiang Wang, Chairman and Chief Executive Officer of Jacobio, said: &#8220;In the first half of 2025, we reached an important milestone with the\u00a0 approval and launch of Glecirasib in <span class=\"xn-location\">China<\/span>. Through our collaboration with business partners, we significantly alleviated the pressure of R&amp;D investment, enabling the Company to focus resources on advancing our pan-KRAS inhibitor and ADC pipeline. Looking forward, we\u00a0 remain committed \u00a0to a transformative innovation \u00a0strategy, working hand in hand with global partners to accelerate the development of breakthrough therapies and deliver benefits to more cancer patients.&#8221;<\/p>\n<p>Accelerated Progress in Core Programs<\/p>\n<p>JAB-23E73 (pan-KRAS inhibitor):<\/p>\n<ul type=\"disc\">\n<li>The dose-escalation portion of the phase I trials are onging in <span class=\"xn-location\">China<\/span> and the U.S, respectively.<\/li>\n<li>Safety profile: low incidence of skin toxicity (rash observed in 10%, all Grade 1) no Grade \u22653 liver toxicity reported to date.<\/li>\n<li>Favorable PK with predicted exposure.<\/li>\n<li>Multiple partial responses have been observed to date.<\/li>\n<li>Preclinical data to be presented at the AACR-NCI-EORTC International Conference in <span class=\"xn-chron\">October 2025<\/span>.<\/li>\n<li>Phase I results readout expected in the first half of 2026.<\/li>\n<\/ul>\n<p>JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC):<\/p>\n<ul type=\"disc\">\n<li>This program uses a highly potent KRAS G12D inhibitor as the payload.<\/li>\n<li>The candidate demonstrates picomolar (pM)-level cellular activity, compared with nanomolar (nM) typically achieved by oral small molecules.<\/li>\n<li>Unlike oral small molecules usually achieve tumor drug concentrations 1\u201310x higher than plasma levels, the JAB-BX 600 delivers a KRAS G12D inhibitor at 1,000 x higher in tumor, resulting in a substantially wider therapeutic window.<\/li>\n<li>The KRAS G12D inhibitor and EGFR antibody have synergistic effect and durable anti-tumor activity.<\/li>\n<li>IND submission planned for the second half of 2026.<\/li>\n<\/ul>\n<p>Glecirasib (JAB-21822, KRAS G12C inhibitor):<\/p>\n<ul type=\"disc\">\n<li>Approved by <span class=\"xn-location\">China&#8217;s<\/span> NMPA in <span class=\"xn-chron\">May 2025<\/span> for \u22652L KRAS G12C mutant NSCLC, successfully launched in <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Triggered a <span class=\"xn-money\">RMB50 million<\/span> milestone payment in addition to the <span class=\"xn-money\">RMB200 million<\/span> upfront received in 2024.<\/li>\n<li>The full second-line NSCLC dataset has been published in Nature Medicine (Impact Factor: 50).<\/li>\n<li>Phase I\/II data for the combination with <span class=\"xn-money\">SHP2<\/span> inhibitor has been accepted by a top-tier academic journal, with publication\u00a0<span>expected in H2 2025.<\/span><\/li>\n<\/ul>\n<p>Sitneprotafib (JAB-3312, <span class=\"xn-money\">SHP2<\/span> inhibitor):<\/p>\n<ul type=\"disc\">\n<li>Ongoing Phase III registration trial in combination with Glecirasib as first-line NSCLC treatment in <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Translational research published in Clinical Cancer Research (Impact Factor: 10.2), demonstrating significant synergy with Glecirasib.<\/li>\n<\/ul>\n<p>JAB-BX467 (HER2-STING iADC):<\/p>\n<ul type=\"disc\">\n<li>A HER2-targeted ADC carrying a STING agonist, designed to convert &#8220;cold tumors&#8221; into &#8220;hot tumors&#8221; and address the 70% of patients unresponsive to PD-1 inhibitors.<\/li>\n<li>Currently in IND-enabling stage, with IND filing planned for H2 2026.<\/li>\n<\/ul>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span> and <span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 30, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Jacobio Pharma (1167.HK) today announced its interim results for the six months ended <span class=\"xn-chron\">June 30, 2025<\/span>.<\/p>\n<p>During the reporting period, the Company achieved revenue of <span class=\"xn-money\">RMB45.7 million<\/span>, representing a 100% increase compared with the same period in 2024. Research and development (R&amp;D) expenses amounted to \u00a0RMB93.2 million. The net loss for the first half of 2025 was <span class=\"xn-money\">RMB59.0 million<\/span>, \u00a0narrowing by 65.1% compared with the same period in 2024. As of <span class=\"xn-chron\">June 30, 2025<\/span>, Jacobio maintained cash and bank balances, and investments in capital protected structure deposits, totaling <span class=\"xn-money\">RMB1,07billion<\/span>, along with <span class=\"xn-money\">RMB270 million<\/span> bank credit available which provides sufficient and stable liquidity to support our R&amp;D activities.<\/p>\n<p>Dr. Yinxiang Wang, Chairman and Chief Executive Officer of Jacobio, said: &#8220;In the first half of 2025, we reached an important milestone with the\u00a0 approval and launch of Glecirasib in <span class=\"xn-location\">China<\/span>. Through our collaboration with business partners, we significantly alleviated the pressure of R&amp;D investment, enabling the Company to focus resources on advancing our pan-KRAS inhibitor and ADC pipeline. Looking forward, we\u00a0 remain committed \u00a0to a transformative innovation \u00a0strategy, working hand in hand with global partners to accelerate the development of breakthrough therapies and deliver benefits to more cancer patients.&#8221;<\/p>\n<p>Accelerated Progress in Core Programs<\/p>\n<p>JAB-23E73 (pan-KRAS inhibitor):<\/p>\n<ul type=\"disc\">\n<li>The dose-escalation portion of the phase I trials are onging in <span class=\"xn-location\">China<\/span> and the U.S, respectively.<\/li>\n<li>Safety profile: low incidence of skin toxicity (rash observed in 10%, all Grade 1) no Grade \u22653 liver toxicity reported to date.<\/li>\n<li>Favorable PK with predicted exposure.<\/li>\n<li>Multiple partial responses have been observed to date.<\/li>\n<li>Preclinical data to be presented at the AACR-NCI-EORTC International Conference in <span class=\"xn-chron\">October 2025<\/span>.<\/li>\n<li>Phase I results readout expected in the first half of 2026.<\/li>\n<\/ul>\n<p>JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC):<\/p>\n<ul type=\"disc\">\n<li>This program uses a highly potent KRAS G12D inhibitor as the payload.<\/li>\n<li>The candidate demonstrates picomolar (pM)-level cellular activity, compared with nanomolar (nM) typically achieved by oral small molecules.<\/li>\n<li>Unlike oral small molecules usually achieve tumor drug concentrations 1\u201310x higher than plasma levels, the JAB-BX 600 delivers a KRAS G12D inhibitor at 1,000 x higher in tumor, resulting in a substantially wider therapeutic window.<\/li>\n<li>The KRAS G12D inhibitor and EGFR antibody have synergistic effect and durable anti-tumor activity.<\/li>\n<li>IND submission planned for the second half of 2026.<\/li>\n<\/ul>\n<p>Glecirasib (JAB-21822, KRAS G12C inhibitor):<\/p>\n<ul type=\"disc\">\n<li>Approved by <span class=\"xn-location\">China&#8217;s<\/span> NMPA in <span class=\"xn-chron\">May 2025<\/span> for \u22652L KRAS G12C mutant NSCLC, successfully launched in <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Triggered a <span class=\"xn-money\">RMB50 million<\/span> milestone payment in addition to the <span class=\"xn-money\">RMB200 million<\/span> upfront received in 2024.<\/li>\n<li>The full second-line NSCLC dataset has been published in Nature Medicine (Impact Factor: 50).<\/li>\n<li>Phase I\/II data for the combination with <span class=\"xn-money\">SHP2<\/span> inhibitor has been accepted by a top-tier academic journal, with publication\u00a0<span>expected in H2 2025.<\/span><\/li>\n<\/ul>\n<p>Sitneprotafib (JAB-3312, <span class=\"xn-money\">SHP2<\/span> inhibitor):<\/p>\n<ul type=\"disc\">\n<li>Ongoing Phase III registration trial in combination with Glecirasib as first-line NSCLC treatment in <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Translational research published in Clinical Cancer Research (Impact Factor: 10.2), demonstrating significant synergy with Glecirasib.<\/li>\n<\/ul>\n<p>JAB-BX467 (HER2-STING iADC):<\/p>\n<ul type=\"disc\">\n<li>A HER2-targeted ADC carrying a STING agonist, designed to convert &#8220;cold tumors&#8221; into &#8220;hot tumors&#8221; and address the 70% of patients unresponsive to PD-1 inhibitors.<\/li>\n<li>Currently in IND-enabling stage, with IND filing planned for H2 2026.<\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31214","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31214"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31214\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}